Skip to main content

Clinical development of TA-101 for the treatment of rheumatoid arthritis

Objective

The aim of TA101GOCLIN Project is to take TA101 into the clinical stage of development for rheumatoid arthritis and prepare the product for a novel mode of administration in the market of biologic therapeutics.
Rheumatoid Arthritis is still today a debilitating disease with an unmet medical need for effective and reasonably priced treatments despite much effort to cure or control the disease. TA101 is a small domain antibody that is being developed for the treatment of rheumatoid arthritis and has passed through preclinical efficacy studies with much success. TA101 will now undergo an upscaling process of production to enter clinical trials. TA101GOCLIN project is within the scope of the clinical development of TA101 and is aimed at providing safety data in humans through a clinical trial of Phase Ia and Ib.

Concomitantly, TA101GOCLIN will develop a novel mode of administration for TA101 to be used after project end. This will provide a major competitive advantage for the product already during development stages. The innovative administration will use microneedle patches, a new method that allows the autonomous administration of the drug through the skin without the pain of conventional injections.

To achieve the above mentioned objectives, TA101GOCLIN gathered three competitive SMEs from Portugal, Belgium and The Netherlands. TechnoPhage, Q-Biologicals and MyLife Technologies, respectively, will be responsible for developing the clinical data of Phase I for TA101, develop an upscale method for production of the drug, and develop the microneedle device for administration of TA101.

Overall, TA101GOCLIN holds the promise that an innovative product for the treatment of Rheumatoid Arthritis will enter the clinical phases of development with the confidence that the technologies that are at its base will create a new solution for the patients, with the major benefits of efficacy, safety, convenience and affordability.

Call for proposal

FP7-SME-2013
See other projects for this call

Funding Scheme

BSG-SME - Research for SMEs

Coordinator

TECHNOPHAGE INVESTIGACAO E DESENVOLVIMENTO EM BIOTECNOLOGIA SA
Address
Avenida Professor Egas Moniz Edificio Egas Moniz Piso 2 Sala A8
1649 028 Lisboa
Portugal
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 966 064,40
Administrative Contact
Sofia Corte-Real (Dr.)

Participants (6)

Q-BIOLOGICALS NV
Belgium
EU contribution
€ 274 888,50
Address
Technologiepark 4
9052 Gent
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Annie Van Broekhoven (Prof.)
MICROCREATE BV
Netherlands
EU contribution
€ 6 499,20
Address
Rechterlaan 3
7535 CH Enschede
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
K Ma (Mr.)
SGS BELGIUM NV
Belgium
EU contribution
€ 2 000
Address
Noorderlaan 87
2030 Antwerpen
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Antoine Briffaux (Mr.)
ADHEXPHARMA
France
EU contribution
€ 8 787
Address
Rue De Lubeck 30
75016 Paris
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Thomas Daniel-Robin (Mr.)
ARTES BIOTECHNOLOGY GmbH
Germany
EU contribution
€ 17 600
Address
Elisabeth-selbert-str. 9
40764 Langenfeld
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Michael Piontek (Mr.)
AMSPAR BV
Netherlands
EU contribution
€ 82 089
Address
Bellamystraat 27 D
1053BG Amsterdam
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Pieter Vos (Mr.)